{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:39:53Z","timestamp":1790278793052,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":885,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002996","name":"Dutch Heart Foundation","doi-asserted-by":"crossref","award":["2020T058"],"award-info":[{"award-number":["2020T058"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002996","name":"Dutch Heart Foundation","doi-asserted-by":"crossref","award":["2018T059"],"award-info":[{"award-number":["2018T059"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Amsterdam Cardiovascular Sciences (ACS) Institute, Amsterdam, The Netherlands"},{"DOI":"10.13039\/501100003246","name":"Netherlands Organisation for Scientific Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Impaired myocardial energy homeostasis plays an import role in the pathophysiology of heart failure with preserved ejection fraction (HFpEF). Left ventricular relaxation has a high energy demand, and left ventricular diastolic dysfunction has been related to impaired energy homeostasis. This study investigated whether trimetazidine, a fatty acid oxidation inhibitor, could improve myocardial energy homeostasis and consequently improve exercise haemodynamics in patients with HFpEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The DoPING-HFpEF trial was a phase II single-centre, double-blind, placebo-controlled, randomized cross-over trial. Patients were randomized to trimetazidine treatment or placebo for 3 months and switched after a 2-week wash-out period. The primary endpoint was change in pulmonary capillary wedge pressure, measured with right heart catheterization at multiple stages of bicycling exercise. Secondary endpoint was change in myocardial phosphocreatine\/adenosine triphosphate, an index of the myocardial energy status, measured with phosphorus-31 magnetic resonance spectroscopy. The study included 25 patients (10\/15 males\/females; mean (standard deviation) age, 66 (10) years; body mass index, 29.8 (4.5) kg\/m2); with the diagnosis of HFpEF confirmed with (exercise) right heart catheterization either before or during the trial. There was no effect of trimetazidine on the primary outcome pulmonary capillary wedge pressure at multiple levels of exercise (mean change 0 [95% confidence interval, 95% CI \u22122, 2] mmHg over multiple levels of exercise, P = 0.60). Myocardial phosphocreatine\/adenosine triphosphate in the trimetazidine arm was similar to placebo (1.08 [0.76, 1.76] vs. 1.30 [0.95, 1.86], P = 0.08). There was no change by trimetazidine compared with placebo in the exploratory parameters: 6-min walking distance (mean change of \u22126 [95% CI \u221218, 7] m vs. \u22125 [95% CI \u221222, 22] m, respectively, P = 0.93), N-terminal pro-B-type natriuretic peptide (5 (\u2212156, 166) ng\/L vs. \u221213 (\u2212172, 147) ng\/L, P = 0.70), overall quality-of-life (KCCQ and EQ-5D-5L, P = 0.78 and P = 0.51, respectively), parameters for diastolic function measured with echocardiography and cardiac magnetic resonance, or metabolic parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Trimetazidine did not improve myocardial energy homeostasis and did not improve exercise haemodynamics in patients with HFpEF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14418","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T06:39:46Z","timestamp":1690958386000},"page":"2998-3010","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Trimetazidine in Heart Failure with Preserved Ejection Fraction: A Randomized Controlled Cross-Over Trial"],"prefix":"10.1093","volume":"10","author":[{"given":"Arno A.","family":"van de Bovenkamp","sequence":"first","affiliation":[{"name":"Department of Cardiology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam , Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Cardiovascular Sciences , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiki T. J.","family":"Geurkink","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank T.P.","family":"Oosterveer","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances S. de","family":"Man","sequence":"additional","affiliation":[{"name":"Amsterdam Cardiovascular Sciences , Amsterdam ,","place":["The Netherlands"]},{"name":"Department of Pulmonary Medicine, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter E.M.","family":"Kok","sequence":"additional","affiliation":[{"name":"Amsterdam Cardiovascular Sciences , Amsterdam ,","place":["The Netherlands"]},{"name":"Department of Clinical and Experimental Cardiology, Amsterdam University Medical Centers, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick N.A.","family":"Bronzwaer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zaans Medical Center , Zaandam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cor P.","family":"Allaart","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam , Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Cardiovascular Sciences , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aart J.","family":"Nederveen","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert C.","family":"van Rossum","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam , Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Cardiovascular Sciences , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianus J.","family":"Bakermans","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Louis","family":"Handoko","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam , Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Cardiovascular Sciences , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"2026012114082469600_ehf214418-bib-0001","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114082469600_ehf214418-bib-0002","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nrcardio.2016.203","article-title":"Expert consensus document: mitochondrial function as a therapeutic target in heart failure","volume":"14","author":"Brown","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2026012114082469600_ehf214418-bib-0003","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.118.036259","article-title":"Mitochondrial dysfunction in heart failure with preserved ejection fraction","volume":"139","author":"Kumar","year":"2019","journal-title":"Circulation"},{"key":"2026012114082469600_ehf214418-bib-0004","first-page":"860","article-title":"Complex energy metabolic changes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction","volume":"33","author":"De Jong","year":"2017","journal-title":"Can J Cardiol"},{"key":"2026012114082469600_ehf214418-bib-0005","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jacc.2009.05.012","article-title":"Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency","volume":"54","author":"Phan","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026012114082469600_ehf214418-bib-0006","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/CIRCULATIONAHA.121.054858","article-title":"Energetic basis for exercise-induced pulmonary congestion in heart failure with preserved ejection fraction","volume":"144","author":"Burrage","year":"2021","journal-title":"Circulation"},{"key":"2026012114082469600_ehf214418-bib-0007","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijcard.2015.11.060","article-title":"Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure","volume":"203","author":"Lopatin","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026012114082469600_ehf214418-bib-0008","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/eurheartj\/ehi816","article-title":"Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine\/adenosine triphosphate ratio in patients with heart failure","volume":"27","author":"Fragasso","year":"2006","journal-title":"Eur Heart J"},{"key":"2026012114082469600_ehf214418-bib-0009","first-page":"11","article-title":"Trimetazidine in heart failure","author":"Shu","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026012114082469600_ehf214418-bib-0010","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1161\/CIRCULATIONAHA.108.778019","article-title":"Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy","volume":"118","author":"Tuunanen","year":"2008","journal-title":"Circulation"},{"key":"2026012114082469600_ehf214418-bib-0011","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jacc.2011.11.027","article-title":"Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis","volume":"59","author":"Zhang","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026012114082469600_ehf214418-bib-0012","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1475-2840-2-16","article-title":"Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study","volume":"2","author":"Rosano","year":"2003","journal-title":"Cardiovasc Diabetol"},{"key":"2026012114082469600_ehf214418-bib-0013","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.ehj.2004.06.034","article-title":"Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease","volume":"25","author":"Vitale","year":"2004","journal-title":"Eur Heart J"},{"key":"2026012114082469600_ehf214418-bib-0014","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12471-020-01407-z","article-title":"TrimetaziDine as a performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study","volume":"28","author":"van de Bovenkamp","year":"2020","journal-title":"Neth Heart J"},{"key":"2026012114082469600_ehf214418-bib-0015","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008935","article-title":"The value of passive leg raise during right heart catheterization in diagnosing heart failure with preserved ejection fraction","volume":"15","author":"van de Bovenkamp","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026012114082469600_ehf214418-bib-0016","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2017.00939","article-title":"Human cardiac 31P-MR spectroscopy at 3 tesla cannot detect failing myocardial energy homeostasis during exercise","volume":"8","author":"Bakermans","year":"2017","journal-title":"Front Physiol"},{"key":"2026012114082469600_ehf214418-bib-0017","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","article-title":"Dutch tariff for the five-level version of EQ-5D","volume":"19","author":"Versteegh","year":"2016","journal-title":"Value Health"},{"key":"2026012114082469600_ehf214418-bib-0018","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/aps.2010.31","article-title":"Improvement of mechanical heart function by trimetazidine in db\/db mice","volume":"31","author":"Li","year":"2010","journal-title":"Acta Pharmacol Sin"},{"key":"2026012114082469600_ehf214418-bib-0019","first-page":"940","article-title":"Trimetazidine therapy prevents obesity-induced cardiomyopathy in mice","volume":"30","author":"Ussher","year":"2014","journal-title":"Can J Cardiol"},{"key":"2026012114082469600_ehf214418-bib-0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12967-016-0849-1","article-title":"Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagy","volume":"14","author":"Zhang","year":"2016","journal-title":"J Transl Med"},{"key":"2026012114082469600_ehf214418-bib-0021","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/A:1015380609464","article-title":"Energy metabolism in the hypertrophied heart","volume":"7","author":"Sambandam","year":"2002","journal-title":"Heart Fail Rev"},{"key":"2026012114082469600_ehf214418-bib-0022","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1161\/01.RES.0000086964.07404.A5","article-title":"Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase","volume":"93","author":"Lopaschuk","year":"2003","journal-title":"Circ Res"},{"key":"2026012114082469600_ehf214418-bib-0023","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1161\/CIRCULATIONAHA.122.061846","article-title":"Myocardial metabolomics of human heart failure with preserved ejection fraction","volume":"147","author":"Hahn","year":"2023","journal-title":"Circulation"},{"key":"2026012114082469600_ehf214418-bib-0024","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial fatty acid metabolism in health and disease","volume":"90","author":"Lopaschuk","year":"2010","journal-title":"Physiol Rev"},{"key":"2026012114082469600_ehf214418-bib-0025","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/jmri.27531","article-title":"Quantification of myocardial creatine and triglyceride content in the human heart: precision and accuracy of in vivo proton magnetic resonance spectroscopy","volume":"54","author":"Bakermans","year":"2021","journal-title":"J Magn Reson Imaging"},{"key":"2026012114082469600_ehf214418-bib-0026","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1755-5922.2011.00275.x","article-title":"Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans","volume":"30","author":"Bucci","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"2026012114082469600_ehf214418-bib-0027","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","article-title":"Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects","volume":"167","author":"Dyck","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"2026012114082469600_ehf214418-bib-0028","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012114082469600_ehf214418-bib-0029","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF03190575","article-title":"Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers","volume":"29","author":"G\u00e9nissel","year":"2004","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2026012114082469600_ehf214418-bib-0030","volume-title":"Servier"},{"key":"2026012114082469600_ehf214418-bib-0031","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021165","article-title":"Validation of the 2016 ASE\/EACVI guideline for diastolic dysfunction in patients with unexplained dyspnea and a preserved left ventricular ejection fraction","volume":"10","author":"van de Bovenkamp","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026012114082469600_ehf214418-bib-0032","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004750","article-title":"Pulmonary capillary wedge pressure patterns during exercise predict exercise capacity and incident heart failure","volume":"11","author":"Eisman","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026012114082469600_ehf214418-bib-0033","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1016\/j.jacc.2020.10.005","article-title":"Effect of Empagliflozin on hemodynamics in patients with heart failure and reduced ejection fraction","volume":"76","author":"Omar","year":"2020","journal-title":"J Am Coll Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/5\/2998\/66227737\/eschf_10_5_2998.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/5\/2998\/66227737\/eschf_10_5_2998.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:09:04Z","timestamp":1769022544000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/5\/2998\/8284456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,8,2]]},"published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14418","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,8,2]]},"assertion":[{"value":"2023-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}